Global Overt Hepatic Encephalopathy Market Size, Share, and COVID-19 Impact Analysis, By Type (Covert and Overt), By Treatment (Lactulose, Antibiotics, Probiotics, Branched-Chain Amino Acids, Liver Transplantation, and others), By Application (Hospitals, Research Institutes, Clinics, Surgical Centers), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032.Industry: Healthcare
Global Overt Hepatic Encephalopathy Market Insights Forecasts to 2032
- The Global Overt Hepatic Encephalopathy Market Size was valued at USD 180.2 Million in 2022.
- The Market is Growing at a CAGR of 8.2% from 2022 to 2032.
- The Worldwide Overt Hepatic Encephalopathy Market size is expected to reach USD 397.5 Million by 2032.
- Europe is expected to Grow the fastest during the forecast period.
Get more details on this report -
The Global Overt Hepatic Encephalopathy Market Size is expected to reach USD 397.5 million by 2032, at a CAGR of 8.2% during the forecast period 2022 to 2032. The overt hepatic encephalopathy market will have increasing growth due to an increase in disease instances, which will lead to a variety of treatment alternatives. The lack of licensed therapies creates a space for developing therapies, and as a result, the industry will see enormous prospects. In the market, there is an increasing demand for pharmaceuticals that are safe, effective, and provide the best possible cure.
When the liver is severely damaged and unable to filter poisons from the blood, a condition known as overt hepatic encephalopathy. These toxins then build up in the brain, affecting mental processes and behavior. Overt hepatic encephalopathy is a dangerous illness that can result in coma or death. It appears in the cases of cirrhotic patients. It causes liver damage, which affects the state of consciousness. During clinical care, roughly 55% of cirrhotic patients' development chances improve. Based on severity, hepatic encephalopathy is classified into two types: covert (CHE) and overt (CHE). Overt Hepatic Encephalopathy is related to higher hospitalization and mortality rates and a lower quality of life. Overt hepatic encephalopathy symptoms include a metabolic imbalance, gastrointestinal hemorrhage, and liver infection. Overt hepatic encephalopathy is characterized by evident, external signs and symptoms in the affected persons.
This research report categorizes the global overt hepatic encephalopathy market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global overt hepatic encephalopathy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global overt hepatic encephalopathy market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Overt Hepatic Encephalopathy Market Report Coverage
|Market Size in 2021:||USD 180.2 Million|
|Forecast Period 2022-2032 CAGR:||8.2%|
|2032 Value Projection:||USD 397.5 Million|
|Historical Data for:||2020-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||120|
|Segments covered:||By Type, By Treatment, By Application, By Region.|
|Companies Covered:||Alfa Wassermann S.P.A, Rebiotix Inc., Cosmo Pharmaceuticals S.P.A, Spherium Biomed S.L, Horizon Pharma Plc, Umecrine Cognition AB, Ocera Therapeutics Inc., Kannalife Sciences Inc., Bausch Health Companies Inc., ASKA Pharmaceutical Co., Ltd, Norgine BV, Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Inc., Abbott Laboratories, Bausch Health Companies Inc., Lupin Limited|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Because of the increasing prevalence of disease cases, the market for overt hepatic encephalopathy will expand at a quicker rate, leading to a range of treatment options. Also, the growing number of cirrhosis patients is a primary factor driving the global overt hepatic encephalopathy market. Moreover, the rising awareness of the symptoms and diagnosis of overt hepatic encephalopathy is propelling the overt hepatic encephalopathy market. Growing emphasis on the development of innovative solutions by industry participants resulted in market growth throughout the forecast period. Furthermore, the availability of novel and creative medicines for the treatment of overt hepatic encephalopathy is driving the market. The increasing number of clinical trials on novel therapies for overt hepatic encephalopathy and the development of key players to meet the public’s demand will accelerate the market to reach its value during the forecast period.
A lack of understanding of clinical courses and relevance may hamper the market's growth. The high cost of rifaximin for the treatment of hepatic encephalopathy is the primary factor limiting the growth of the Global Overt Hepatic Encephalopathy Market. For example, according to the National Center for Biotechnology Information, hepatic encephalopathy is the second most prevalent reason for hospitalization in individuals with liver cirrhosis in the United States, after only ascites. As liver cirrhosis is an irreversible condition, numerous research studies would recommend long-term, possibly life-long, rifaximin therapy to prevent the recurrence of hepatic encephalopathy. During the forecast period, all of these factors are projected to restrict the Global Overt Hepatic Encephalopathy Market.
- In 2022, the overt segment is dominating the market with the largest market share over the forecast period.
Based on the type, the global overt hepatic encephalopathy market is segmented into covert and overt. Among these segments, the overt segment is dominating the market due to the overt segment is predicted to expand with the biggest market share in 2021. The overt segment in the worldwide overt hepatic encephalopathy market is predicted to develop as awareness of liver illnesses grows. Also, Cirrhosis prevalence, rising traffic accident instances, increased expenses for healthcare, and other reasons are boosting the global overt hepatic encephalopathy market. According to the WHO, around 30-40% of patients in the United States have overt hepatic encephalopathy.
- In 2022, the lactulose segment is influencing the largest market share over the forecast period.
Based on the treatment, the global overt hepatic encephalopathy market is bifurcated into various segments includes, including lactulose, antibiotics, probiotics, branched-chain amino acids, liver transplantation, and others. Among these segments, the lactulose category will have the largest market share due to its capacity to minimize ammonia production in the gut by generating an aggressive environment for the harmful microorganisms in the intestine.
- In 2022, the hospital segment held the largest market share during the forecast period.
On the basis of application, the global overt hepatic encephalopathy market is classified into different segments such as hospitals, research institutes, clinics, and surgical centers. Throughout these segments, the hospital segment is expected to influence the market over the forecast period, because of increased knowledge of early detection and treatment of the disease. Moreover, an increase in incidence rate, combined with an increase in inpatient visits seeking medical care for brain symptoms, suggests the presence of widespread overt encephalopathy around the world, which will drive market expansion during the projection period.
Regional Segment Analysis of the overt hepatic encephalopathy market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is leading the market with the largest market share during the forecast period
Get more details on this report -
North America is dominating the significant market growth over the forecast period due to the region's supremacy is predicted to continue during the forecast period. This is due to increased knowledge of HOE, the availability of effective treatment approaches, and the increasing prevalence of liver-related illnesses. Furthermore, the existence of important businesses conducting considerable research to create breakthrough medicines would propel expansion even further. Moreover, the increase in the number of geriatric populations and the rising number of people suffering from cirrhosis led to the growth of overt hepatic encephalopathy in this region.
Europe is expected to experience high revenue market growth during the forecast period, owing to an increase in R&D activities for the treatment and management of liver ailments, which is driving the expansion of the global overt hepatic encephalopathy market in this sector. Furthermore, an increase in the prevalence of high overt hepatic encephalopathy caused by alcohol intake is propelling the market growth. This region has a high prevalence of overt hepatic encephalopathy.
The report offers the appropriate analysis of the key organizations/companies involved within the global overt hepatic encephalopathy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Alfa Wassermann S.P.A
- Rebiotix Inc.
- Cosmo Pharmaceuticals S.P.A
- Spherium Biomed S.L
- Horizon Pharma Plc
- Umecrine Cognition AB
- Ocera Therapeutics Inc.
- Kannalife Sciences Inc.
- Bausch Health Companies Inc.
- ASKA Pharmaceutical Co., Ltd
- Norgine BV
- Mallinckrodt Pharmaceuticals
- Ferring Pharmaceuticals Inc.
- Abbott Laboratories
- Bausch Health Companies Inc.
- Lupin Limited
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In April 2022, Salix Pharmaceuticals, a gastroenterology division of Bausch Health Companies Inc, the world's largest specialty pharmaceutical firm, launched its gastrointestinal illness prevention and treatment. The business presented four posters data for XIFAXAN (rifaximin) and RELISTO (methylnaltrexone bromide) at the Society of Hospital Medicine (SHM) Converge 2022 annual meeting, which will be held from April 7 to 10, 2022, in Nashville, Tennessee. In comparison to Lactulose alone, Rifaximin Treatment for Hepatic Encephalopathy can reduce the number of emergency days in the Emergency Department.
This study forecasts global, regional, and country revenue from 2022 to 2032. Spherical Insights has segmented the Global Overt Hepatic Encephalopathy Market based on the below-mentioned segments:
Global Overt Hepatic Encephalopathy Market, By Type
Global Overt Hepatic Encephalopathy Market, By Treatment
- Branched-Chain Amino Acids
- Liver Transplantation
Global Overt Hepatic Encephalopathy Market, By Application
- Research Institutes
- Surgical Centers
Overt Hepatic Encephalopathy Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?